Blog | HemaCare

Developing Treatments for Sclerosis Patients

Mar 19, 2019 10:30:00 AM / by Stacy Matthews Branch, DVM, PhD posted in PBMCs, peripheral blood mononuclear cells, Stem Cells, immunosuppressive therapy


Systemic sclerosis, also called scleroderma, progressive systemic sclerosis, or CREST syndrome, is a rare autoimmune connective tissue disease with fibrosis and vasculopathy. Patients often have sclerotic, thickened skin, but some experience significant organ damage. Immunosuppressive therapy is a common approach to patients with systemic sclerosis, but there is a subset of patients that do not respond well to treatment.

Read More

Chronic Stress May Increase Cellular Aging in Women

Oct 16, 2018 8:30:00 AM / by Stacy Matthews Branch, DVM, PhD posted in PBMCs


A study using peripheral blood mononuclear cells (PBMCs) demonstrates the link between women’s stress levels and shortened telomere length.

Stress is one of the body’s major means of reacting to life challenges, dangers, and difficulties. Various chemicals are released in the body that promote cellular and organ-level changes needed to cope with, adjust, and respond to stressors. The effects that are felt with chronic stress range anywhere from pain, digestive problems, and fatigue to sexual, cognitive, immunological, and emotional effects. Women are particularly vulnerable to the effects of stress due to unique challenges they face, including gender and race-based discrimination and forms of victimization.

Read More

PBMCs and Psoriasis Treatments

Jun 18, 2018 10:11:00 AM / by Stacy Matthews Branch, DVM, PhD posted in B Cells, PBMC, PBMCs, peripheral blood mononuclear cells, Helper T Cells, immune cells


Scientists examined the peripheral blood mononuclear cell (PBMC) profiles of patients with and without psoriasis, including those that both responded to classic treatments and didn’t respond. They then analyzed the profile of those immune cell types. Here are the results of that study.

There are often differences among patient populations for a given disease in how effective a treatment provides medical relief. An important part of personalized medicine is identifying patients that are not likely to respond to a treatment regimen for a specific disease or condition. Doing this can limit the loss of time and resources in using ineffective treatments and can allow the use of personalized treatments in these populations.

Read More

Promising Treatment for Multiple Myeloma on the Horizon

Apr 16, 2018 10:11:00 AM / by Stacy Matthews Branch, DVM, PhD posted in PBMC, PBMCs, peripheral blood mononuclear cells


Researchers believe combining elotuzumab and PBMC treatments with ASCT and lenalidomide maintenance may be an effective treatment option for multiple myeloma.

Multiple myeloma (MM) is a hematological cancer of bone marrow plasma cells. In MM, the antibody-producing plasma cells transform into malignant myeloma cells that produce abnormal antibodies (M proteins). When M proteins accumulate, they outnumber and overcrowd the normal antibodies. Patients with MM can experience bone and kidney damage, anemia, and an impaired immune system.

Read More

The Role of PBMCs in Chronic Fatigue

Feb 28, 2018 10:15:00 AM / by Stacy Matthews Branch, DVM, PhD posted in PBMC, PBMCs


New research using PBMCs has uncovered the role of cellular energy pathways in chronic fatigue syndrome.

Chronic fatigue syndrome (CFS), also known as myalgic encephalomyelitis, but recently referred to as systemic exercise intolerance disease, is a debilitating disease without a known cause. Historically, it has been thought of as a manifestation of a psychological condition. Some references still speculate that psychological stress may be a trigger, as well as viral infection or hormone imbalances. Whatever the cause, CFS is characterized by extreme fatigue that cannot be explained by an obvious medical condition. It is worse after physical or mental activity, yet it is not relieved by resting.

Read More

Subscribe Here!

Posts by Topic

see all

Recent Posts